Remix Therapeutics is a clinical-stage biotechnology company focused on small molecule therapies designed to reprogram RNA processing. Its lead program is REM-422, which the company intends to advance through clinical development. Remix uses a REMaster technology platform to identify RNA processing patterns and target key RNA processing steps to modulate gene expression. The company describes RNA processing as the pathway that controls gene and protein expression and says its approach can alter how genes are read to correct, enhance, or eliminate gene messages and address disease drivers at their origin. Remix is led by CEO and Ph.D. Peter Smith. The company raised $60M to support clinical development of REM-422 and further advance its pipeline of RNA processing–targeted therapeutics. Remix Therapeutics develops small-molecule therapeutics that precisely target RNA processing to enhance, eliminate, or correct protein function in disease. The company leverages data analytics, high-throughput screening technologies, and next-generation chemistry through its REMaster drug discovery platform. Remix is advancing a pipeline of RNA processing–targeted therapeutics and recently entered a strategic collaboration with Janssen Pharmaceutica NV to discover and develop modulators of RNA processing. Led by Co-Founder and CEO Peter Smith, Ph.D., the company aims to use its platform to identify novel small-molecule opportunities across disease areas. The company raised capital to support further development of the REMaster platform and progression of its therapeutic pipeline. Remix Therapeutics develops small‑molecule therapies designed to reprogram RNA processing using its proprietary REMaster technology platform. The company leverages data analytics, bespoke high‑throughput screening, structural biology and next‑generation chemistry to identify and target RNA processing steps. Its oral small‑molecule approach is intended to enable systemic and CNS exposure. Remix says this modality could address a broad range of diseases, including cancers, CNS disorders and rare diseases. The company launched with an $81 million financing to advance the REMaster platform and a pipeline of RNA‑processing targeted therapeutics. Leadership and scientific direction include Co‑Founder, President and CSO Pete Smith and a board composed of investors and scientific experts from Foresite Capital, Atlas Venture, The Column Group and Arch Venture.

Total raised

$211M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2024